At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings…
AVEO (AVEO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
NEW YORK, May 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, LUV, AVEO, APA, and THMO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecti…
The "Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.
Tracklist: Tracks: 01. Aveo – In My Heart (Michael Milov Edit) 3:27 02. Unit Of Trance – Be Quiet (Radio Edit) 3:40 03. Carl Daylim – My Last Hope (Radio Edit) 4:05 04. Hiromori Aso – Blink Dagger (Short Mix) 2:55 05. Digital Rush – Everglow (Radio Edit) 3:58…
Investors need to pay close attention to AVEO Pharmaceuticals (AVEO) stock based on the movements in the options market lately.
NEW YORK, May 1, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, LUV, AVEO, APA, and THMO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecti…
AVEO (AVEO) delivered earnings and revenue surprises of -4.00% and -65.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
General Motors has Mexico's clearance to restart plants there with safety protocols similar to those in the United States. Ford and FCA wait for OK.
AVEO Oncology (NASDAQ: AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the health and well-being of its stockholders, employees and communities, the location of its 2020 Annual Meeting of Stockholders (the "Annual Meeting") has been changed to a virtual meeting. As previously announced, the Annual Meeting will be held on June 10, 2020 at 10:00 a.m. Eastern Time, but will be held via live audio webcast. Stockholders will be able to attend the Annual Meeting only via the webcast.
AVEO Pharmaceuticals (AVEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, t…
DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Cancer Monoclonal Antibody Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering. This report provides an understanding and access to the cancer monoclonal antibo…
AVEO ceases the phase II CyFi-2 study on ficlatuzumab plus high-dose cytarabine for treating patients with relapsed/refractory acute myeloid leukemia to combat the COVID-19 outbreak.
Chivis Martinez Borderland Beat El Diario Chihuahua The right hand of 'El Iraqui’ arrested, Los Aztecas Alexis David LM nickname...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 12) AbbVie Inc (NYSE: ABBV ) Agile Therapeutics Inc (NASDAQ: ...
AVEO Oncology (NASDAQ: AVEO) and Biodesix, Inc. today announced the discontinuation of their CyFi-2 study, a randomized Phase 2 clinical study evaluating ficlatuzumab, AVEO’s potent hepatocyte growth factor (HGF) inhibitory antibody product candidate, in combination with high-dose cytarabine vs. high-dose cytarabine alone in patients with relapsed and refractory acute myeloid leukemia (AML). This decision is being taken due to the urgent shift among clinical sites toward efforts to combat the COVID-19 pandemic, which has impacted the feasibility of completing the study within the shelf-life of the current ficlatuzumab clinical trial supply. The study has not yet begun patient enrollment.
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2020 and provided a business update.
AVEO Oncology (NASDAQ: AVEO) today reported financial results for the full year ended December 31, 2019 and provided a business update.
Gainers: Hertz Global (NYSE:HTZ) +104%.Euroseas (NASDAQ:ESEA) +35%.Mersana Therapeutics (NASDAQ:MRSN) +34%.StoneCo (NASDAQ:STNE) +26%.RealNetworks (NASDAQ:RNWK)
AVEO (AVEO) delivered earnings and revenue surprises of 51.72% and -63.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Even though AVEO Pharmaceuticals (AVEO) reports narrower-than-estimated loss in the fourth quarter, its revenues miss the mark.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today reported financial results for the first quarter ended March 31, 2020 and provided a business update. “Our recent submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (…
AVEO (AVEO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that due to the public health impact of the novel coronavirus (COVID-19) outbreak and governmental restrictions limiting the number of people who may gather together, and to support the hea…
AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial comparing tivozanib, AVEO’s vascular endothelial growth factor receptor tyrosine kinase inhibitor, to sorafenib in 3rd and 4th line renal cell carcinoma, will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program being held May 29-May 31, 2020.
The "Global Companion Diagnostics Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering.
DUBLIN, May 18, 2020 /PRNewswire/ -- The "Global Companion Diagnostics Partnering Terms and Agreements 2010-2020" report has been added to ResearchAndMarkets.com's offering. This report provides comprehensive understanding and unprecedented access to the comp…
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and a 20% drop in […]
AVEO (AVEO) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AVEO releases results from a phase Ib study on ficlatuzumab in combination with nab-paclitaxel and gemcitabine for treating advanced pancreatic cancer. Shares inch up.
AVEO Oncology (NASDAQ: AVEO) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for tivozanib, the Company’s vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma (RCC).